A phase I/II open-label, first-in-human, multicenter, dose escalation and dose expansion study of OP-1250 monotherapy in adult subjects with advanced and/or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer Meeting Abstract

cited authors

  • Hamilton, Erika; Alemany, Carlos; Lin, Nancy U.; Klein, Pamela M.; Trinh Le; Kushner, Peter J.; Harmon, Cyrus; Zujewski, Jo Anne; Patel, Manish

authors

Publication Date

  • February 1, 2021

webpage

published in

category

volume

  • 81

issue

  • 4